Revolution Medicines, Inc. is advancing its late-stage RAS(ON) pipeline, gaining FDA priority review, and is seen as a potential acquisition target for MRK.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Revolution Medicines, Inc. is advancing its late-stage RAS(ON) pipeline, gaining FDA priority review, and is seen as a potential acquisition target for MRK.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Cuong Do leads BioVie as its CEO. BioVie Inc is listed on the NASDAQ exchange and is seeking FDA review for its drug candidate.
- Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.
- Ligand Pharmaceuticals received FDA approval for its drug Filspari and was listed on the Nasdaq stock exchange.
- FDA approval enables commercial opportunity involving CBRE Group.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.